Exagen reported $12.1M revenue, up 18%. Average revenue per test rose 12% to $165. Management narrowed net loss guidance and targets break-even by mid-2025.
Alpha Score of 49 reflects weak overall profile with strong momentum, poor value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Exagen (NASDAQ: XGN) reported $12.1 million in second-quarter revenue, up 18% from a year earlier. The shift in payer mix pushed average revenue per test up 12% to $165. Commercial insurers now cover 52% of test volume, up from 48% a year ago, while Medicare's share declined.
The company's flagship Avise CTD test saw wider reimbursement coverage during the quarter, a Seeking Alpha analyst noted. Operating cash burn narrowed to $4.1 million from $5.8 million a year earlier. Management cut its full-year net loss forecast to $22 million to $25 million, down from $27 million to $30 million.
Exagen ended the quarter with $32 million in cash. The company said it has enough runway through the end of 2025, assuming current revenue trends hold.
The improvement relies on continued mix shift. If a major commercial payer pulls coverage or renegotiates rates, the ASP gains could reverse. Exagen also faces competition from larger diagnostics firms that can bundle autoimmune testing with other lab services.
Management is targeting break-even by mid-2025, the CFO told analysts on the earnings call. Hitting that target would require maintaining the current ASP trajectory while growing test volume at least 15% annually. The company's progress toward break-even is a key theme in our broader stock market analysis.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.